Posted by Michael Wonder on 25 Apr 2020
Merck resubmits supplemental biologics license applications for Keytruda (pembrolizumab) six week dosing schedule
23 April 2020 - Additional applications filed across all approved adult indications.
Merck today announced the resubmission of its supplemental biologics license applications to the U.S. FDA to update the dosing frequency for Keytruda, to include a 400 mg dose infused over 30 minutes every six weeks, in addition to the currently approved dose of 200 mg every three weeks.
Applications were filed across all adult indications for Keytruda, including monotherapy and combination therapy.
